Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 8/20 | 0.45 |
| ▸ | THRA | P10827 | 6/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | MDH1 | P40925 | 1/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
| ▸ | ACR | P10323 | 1/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.31 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19804655 | 0.87 | THRB (0.41) | THRBTHRAMEN1KMT2ACYP4A11 | |
| SCHEMBL19796928 | 0.84 | THRB (0.41) | THRBTHRAMEN1KMT2ACYP4A11 | |
| SCHEMBL19796925 | 0.82 | THRB (0.39) | THRBTHRAMEN1KMT2AITGB3 | |
| SCHEMBL19796476 | 0.81 | THRB (0.50) | THRBTHRAMEN1KMT2ACYP4A11 | |
| SCHEMBL16657532 | 0.80 | THRB (0.45) | THRBTHRAMEN1KMT2AMAPT | |
| SCHEMBL12154171 | 0.80 | THRB (0.45) | THRBTHRAMEN1KMT2AMAPT | |
| SCHEMBL19804027 | 0.79 | THRB (0.46) | THRBTHRAMEN1KMT2ACYP4A11 | |
| SCHEMBL16996735 | 0.77 | THRB (0.51) | THRBTHRAMEN1KMT2AMAPT | |
| SCHEMBL19797068 | 0.76 | SPHK1 (0.38) | THRBTHRA | |
| SCHEMBL10524746 | 0.76 | RARB (0.44) | THRBTHRAMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | SP1, C1S, AP3D1 | THRB 4323/4885THRA 4376/4885MEN1 1151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.